1-({{(2,5-dioxopyrrolidin-1-yl)oxy}carbonyl}-oxy)ethyl 2-methylpropanoate | 1027104-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-({{(2,5-dioxopyrrolidin-1-yl)oxy}carbonyl}-oxy)ethyl 2-methylpropanoate
• 英文别名: (2,5-Dioxoazolidinyloxycarbonyloxy)ethyl 2-methylpropanoate；2-(2,5-dioxopyrrolidin-1-yl)oxycarbonyloxyethyl 2-methylpropanoate
• CAS: 1027104-22-8
• 化学式: C₁₁H₁₅NO₇
• 分子量: 273.243
• InChiKey: BBNXDPWSLWGJOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  99.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-({{(2,5-dioxopyrrolidin-1-yl)oxy}carbonyl}-oxy)ethyl 2-methylpropanoate 、 (3R)-4-amino-3-{4-chloro-3-[5-(methoxycarbonyl)(2-thienyl)]phenyl}butanoic acid 在 碳酸氢钠 作用下， 以 水 、 乙腈 为溶剂， 生成 (3R)-3-{4-chloro-3-{(5-methoxycarbonyl)(2-thienyl)}phenyl}-4-{[(2-methylpropanoyloxy)ethoxy]carbonylamino}butanoic acid
  参考文献：
  名称：

  GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS

  摘要：

  揭示了作为GABAB受体配体的γ-氨基丁酸衍生物、包括这种衍生物的药物组合物，以及使用这种衍生物和药物组合物治疗疾病的方法。

  公开号：

  US20100267676A1

文献信息

• [EN] PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS<br/>[FR] PROMÉDICAMENTS À BASE DE SS-LACTAME INHIBITEURS DU PROTÉASOME UTILES POUR LE TRAITEMENT DU CANCER ET DE TROUBLES NEURODÉGÉNÉRATIFS
  申请人：VITA API

  公开号：WO2018115497A1

  公开（公告）日：2018-06-28

  The present invention relates generally to proteasome inhibiting β-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formulations of said compounds, and medical uses of said compounds and/or pharmaceutical compositions to treat cancer and neurodegenerative disorders.

  本发明通常涉及抑制蛋白酶体的β-内酰胺化合物，用于治疗癌症和神经退行性疾病。该发明还提供了所述化合物的药物组合物和延长释放配方，以及利用所述化合物和/或药物组合物治疗癌症和神经退行性疾病的医疗用途。
• EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Jandeleit Bernd

  公开号：US20090082464A1

  公开（公告）日：2009-03-26

  Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

  掩蔽的氮取代和氧取代的新戊烷磺酰酯丙戊酸酯前药，包含这种前药的药物组合物，以及使用这种前药和组合物治疗疾病的方法被披露。具体来说，披露了表现出增强口服生物利用度的丙戊酸酯前药和使用丙戊酸酯前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化和疼痛的方法。
• Creatine prodrugs, compositions and uses thereof
  申请人：Gao Qingzhi

  公开号：US20070281996A1

  公开（公告）日：2007-12-06

  Membrane permeable prodrugs of creatine, pharmaceutical compositions comprising membrane permeable prodrugs of creatine, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine or pharmaceutical compositions thereof are disclosed.

  本发明涉及可渗透细胞膜的肌酸前药、含有可渗透细胞膜的肌酸前药的制药组合物，以及治疗缺血、心力衰竭和神经退行性疾病的方法，包括给予肌酸前药或其制药组合物。
• Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
  申请人：Dai Xuedong

  公开号：US20080051458A1

  公开（公告）日：2008-02-28

  Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained release dosage forms are also disclosed.

  本发明公开了α-氨基酸的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备酰氧基烷基氨基甲酸酯前药的方法以及使用酰氧基烷基氨基甲酸酯前药和其制药组合物治疗疾病的方法。本发明还公开了适用于口服缓释剂型的α-氨基酸的酰氧基烷基氨基甲酸酯前药。
• Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
  申请人：XenoPort, Inc.

  公开号：US07531572B2

  公开（公告）日：2009-05-12

  Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained release dosage forms are also disclosed.

  本发明涉及α-氨基酸的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备α-氨基酸酰氧基烷基氨基甲酸酯前药的方法，以及使用α-氨基酸酰氧基烷基氨基甲酸酯前药及其制药组合物治疗疾病的方法。本发明还涉及适用于口服给药的酰氧基烷基氨基甲酸酯前药，该药物使用缓释剂量形式。